| ABO |
P16442
|
ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase
|
Enzyme
|
|
0.427 |
0.885 |
61
|
54 |
| MIR4435-2HG |
|
MIR4435-2 host gene
|
|
|
0.604 |
0.692 |
38
|
56 |
| CASC15 |
|
cancer susceptibility 15
|
|
|
0.603 |
0.577 |
35
|
41 |
| CCDC26 |
Q8TAB7
|
CCDC26 long non-coding RNA
|
|
|
0.647 |
0.615 |
31
|
41 |
| PVT1 |
|
Pvt1 oncogene
|
|
|
0.495 |
0.731 |
27
|
31 |
| HCP5 |
Q6MZN7
|
HLA complex P5
|
|
|
0.595 |
0.808 |
23
|
17 |
| MIR3936HG |
|
MIR3936 host gene
|
|
|
0.861 |
0.269 |
22
|
18 |
| CCDC162P |
|
coiled-coil domain containing 162, pseudogene
|
|
|
0.890 |
0.154 |
21
|
28 |
| BDNF-AS |
|
BDNF antisense RNA
|
|
|
0.638 |
0.538 |
20
|
23 |
| LINC00299 |
Q6ZSB3
|
long intergenic non-protein coding RNA 299
|
|
|
0.743 |
0.346 |
19
|
16 |
| LINC01478 |
|
long intergenic non-protein coding RNA 1478
|
|
|
1.000 |
0.077 |
17
|
15 |
| LINC02341 |
|
long intergenic non-protein coding RNA 2341
|
|
|
0.751 |
0.231 |
16
|
13 |
| CADM3-AS1 |
|
CADM3 antisense RNA 1
|
|
|
1.000 |
0.038 |
14
|
8 |
| VLDLR-AS1 |
|
VLDLR antisense RNA 1
|
|
|
0.821 |
0.115 |
14
|
11 |
| MIR29B2CHG |
|
MIR29B2 and MIR29C host gene
|
|
|
0.839 |
0.192 |
13
|
12 |
| CRTC3-AS1 |
|
CRTC3 antisense RNA 1
|
|
|
0.792 |
0.077 |
13
|
4 |
| IL12A-AS1 |
|
IL12A antisense RNA 1
|
|
|
0.633 |
0.654 |
12
|
27 |
| RERE-AS1 |
|
RERE antisense RNA 1
|
|
|
0.890 |
0.077 |
9
|
7 |
| LINC01221 |
|
long intergenic non-protein coding RNA 1221
|
|
|
1.000 |
0.038 |
9
|
6 |
| LINC02357 |
|
long intergenic non-protein coding RNA 2357
|
|
|
0.805 |
0.231 |
9
|
7 |
| RAB4B-EGLN2 |
|
RAB4B-EGLN2 readthrough (NMD candidate)
|
|
|
0.641 |
0.654 |
8
|
6 |
| JAZF1-AS1 |
|
JAZF1 antisense RNA 1
|
|
|
1.000 |
0.115 |
7
|
3 |
| LINC01229 |
|
long intergenic non-protein coding RNA 1229
|
|
|
0.931 |
0.115 |
7
|
10 |
| SEC1P |
|
secretory blood group 1, pseudogene
|
|
|
0.792 |
0.385 |
7
|
4 |